Pharmacologic Treatments for COVID-19

During corona virus, the FDA has issued an emergency use authorization (EUA) for bamlanivimab, which is a monoclonal antibody given against the spike protein of SARS-CoV-2

Baricitinib or JAK inhibitor is used in combination with remdesivir, in the treatment of suspected or laboratory-confirmed coronavirus disease in hospitalized patients aged 2 years and elderly who require supplemental oxygen, invasive mechanical ventilation. Various other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as possible therapies.